Aldeyra Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2012
Net Income	-30.01	-37.54	-62.02	-57.78	-37.55	-60.83	Upgrade
Depreciation & Amortization	0.26	0.26	0.26	0.26	0.06	0.1	Upgrade
Share-Based Compensation	3.11	5.75	8.29	7.11	7.08	8.08	Upgrade
Other Operating Activities	-4.21	1.2	-3.16	7.85	-7.08	7.66	Upgrade
Operating Cash Flow	-30.85	-30.33	-56.64	-42.56	-37.49	-44.98	Upgrade
Capital Expenditures	0	0	-0.02	-0.01	0	-0.01	Upgrade
Acquisitions	0	0	0	0	0	0.61	Upgrade
Change in Investments	-30.38	30	-29.94	0	29.02	17.88	Upgrade
Investing Cash Flow	-30.38	30	-29.95	-0.01	29.02	18.48	Upgrade
Share Issuance / Repurchase	0.27	0.31	1.22	194.5	41.9	9.25	Upgrade
Debt Issued / Paid	-1.04	-1.04	0	0	0	14.45	Upgrade
Other Financing Activities	-0.53	-0.53	-	-	-	-0.12	Upgrade
Financing Cash Flow	-1.3	-1.27	1.22	194.5	41.9	23.58	Upgrade
Net Cash Flow	-62.54	-1.6	-85.37	151.93	33.43	-2.93	Upgrade
Free Cash Flow	-30.85	-30.33	-56.65	-42.56	-37.49	-44.99	Upgrade
Free Cash Flow Per Share	-0.52	-0.51	-0.97	-0.79	-1.10	-1.66	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).